Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise.
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.

#palsonify

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $139 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases.
Companies worth $10 billion or more are generally described as "large-cap stocks," and VRTX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. VRTX derives its primary competitive strength from its global monopoly in CF treatments, anchored by flagship blockbusters like Trikafta/Katori which generate robust cash flow to fuel its high-impact clinical pipeline.
Dear GameStop Stock Fans, Mark Your Calendars for September 8
SMCI vs. CoreWeave: 1 AI Infrastructure Model Has the Bigger Opportunity
Why **** ysts Think Sellas Life Sciences Stock Can Gain 150% From Here

#vrtx #massachusetts

On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands September 10, and management admitted that paying it without new financing could trip a liquidity covenant and trigger default. Investors are being asked to weigh a genuinely differentiated drug against a genuinely short clock.
The bull case rests on selinexor paired with ruxolitinib, which Karyopharm plans to submit for FDA review this month under the Accelerated Approval Pathway for myelofibrosis. The Phase III SENTRY study found statistically significant, rapid, deep, and sustained spleen volume reductions, along with a preliminary overall survival signal and hints of disease modification. At week 24, the combination nearly doubled the spleen response rate versus ruxolitinib alone, with responses showing up as early as week 12 and holding through week 36 across patient subgroups. Even when ruxolitinib was dosed below 15 milligrams a day, the combination produced SVR35 rates as high as 50%, compared with zero for ruxolitinib alone, suggesting doctors could trim ruxolitinib without losing efficacy.
The overall survival hazard ratio at the time of the topline ******* ysis was 0.43. If cleared, this would be the first approved combination therapy in frontline myelofibrosis, a disease affecting roughly 20,000 people in the US with about 4,000 newly treated each year and no combination option on the market. Karyopharm pegs the peak US revenue opportunity at up to $1 billion and plans to lean on the commercial infrastructure it already runs for XPOVIO, including its KaryForward patient support program, to move quickly if approved. On the existing business, XPOVIO generated $30.8 million in U.S. net product revenue in the quarter, with demand holding roughly flat from a year earlier even as the treatment landscape gets more crowded.
The financial picture is where the caution belongs. Total revenue fell to $33.4 million from $37.9 million a year earlier, largely because Menarini's reimbursement of development costs ended in late 2025, a roughly $6.5 million swing. Net loss widened to $67 million from $37.3 million, and while some of that reflects non-cash mark-to-market adjustments tied to the company's financing structure, the cash balance tells its own story: $65.4 million in cash, equivalents, and investments at quarter end. Management said that funds current plans only through September 2026. A $15.8 million term loan payment is due September 10, and if it goes out without additional financing or a lender waiver, cash would fall below the $10 million minimum liquidity covenant, an event of default.

#september #cash #karyopharm #myelofibrosis

Headquartered in Boston, Massachusetts, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that develops innovative medicines for serious diseases, including cystic fibrosis (CF), sickle cell disease, beta thalassemia, and acute pain.
Moreover, the company is building beyond its approved treatments with potential therapies targeting genetic and other complex conditions, including kidney, metabolic, and neuromuscular diseases.
Here Is How to Play Tesla Stock After Its Robotaxi Breakthrough
Micron Stock Pullback: High Growth, Low Multiple Support Upside
Strategy Just Sold $334 Million in Shares to Build Cash and Buy Back Preferred Stock. This Hits MSTR Stock Holders With Dilution.

#including #headquartered

Veronica Perasso revealed to her Instagram followers that her experience of getting numerous cosmetic treatments made her have some scar tissue, constant health concerns, and body image issues, which she is struggling with. Veronica encouraged younger women to consult qualified professionals before doing the same.
In the second video on her Instagram account regarding her surgeries, Perasso refuted her fans who claimed that the outcome was something to envy.
"Part 2 of the rundown of all my surgeries. Some of you are confused because you guys see my stomach, and some of you think, wow, that's goals. How do you think you didn't look good? Well, because after the surgery, I did not look this way. I was still fat after a liposuction because they removed the fat out of here. Still, my face, my arms, and my legs were not in shape," she said.
She said the liposuction was followed by complications.
"And then I had a lot of fibrosis, it's scar tissue, and it looks so weird, and this is because I got massages, I got it treated," she said.

#veronica #scar #tissue #look

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM), which develops and commercializes therapies for patients with serious and rare diseases, detracted from the fund's performance during the quarter. On August 03, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $98.45 per share. The one-month return of Insmed Incorporated (NASDAQ:INSM) was -12.56%, and its shares lost 11.59% over the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $21.34 billion.
Baron Health Care Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated is a biotechnology company with three lead pulmonology ******* ets that we believe can collectively generate more than $8 billion in peak sales. We are particularly excited about Brinsupri for non-cystic fibrosis bronchiectasis, which we view as a $5 billion-plus opportunity. Despite what we believe has been a strong start to the launch, shares fell after first quarter Brinsupri sales missed expectations as investors focused on early signs of higher treatment discontinuations. Insmed's exit from the Nasdaq-100 Index created additional technical selling pressure. Long term, we continue to view Brinsupri as an important treatment option for the 500,000-plus bronchiectasis patients in the U.S. We remain bullish on the portfolio's long-term fundamentals, including the opportunity for treprostinil palmitil inhalation powder (TPIP), which is being studied for pulmonary arterial hypertension and pulmonary hypertension ******* ociated with interstitial lung disease. Compared to existing inhaled prostanoids that require four daily treatments, once-daily TPIP is more convenient and can be dosed at significantly higher levels, potentially resulting in meaningfully better efficacy."

#fund #baron

Aug 3 (Reuters) - Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust ‌demand for its cystic fibrosis treatments.
The company expects its ‌annual revenue to be between $13.1 billion and $13.2 billion, compared with $12.95 billion to $13.1 billion previously. **** ysts on average expect 2026 revenue of $13.07 billion, according to data compiled by LSEG.
Vertex said its annual outlook excludes the pending Crinetics acquisition and that an updated forecast will be provided after the ‌deal closes, which is ⁠expected in the third quarter.
Here are more details:
• Vertex's $10 billion acquisition of Crinetics expands its reach beyond ⁠cystic fibrosis, adding endocrine disorders to a diversification strategy that already includes povetacicept in kidney, Casgevy in sickle cell and Journavx in pain, **** ysts had said.

#cystic #fibrosis

Crown Prince Haakon of Norway stepped out this week and gave an update on his wife, Crown Princess Mette-Marit, after her lung transplant
"It's only the beginning of a long road to recovery," he told reporters
The mother of three was diagnosed with chronic pulmonary fibrosis in 2018
Crown Princess Mette-Marit of Norway has a "long road to recovery" following her lung transplant last month.
Mette-Marit's husband, Crown Prince Haakon, shared the update this week from the town of Krokstadelva, where he met with residents and rescue workers battling the massive Drammen wildfire.

#norway #princess #marit

SOUTHPORT, England — David Howard was age 7 when he was diagnosed with cystic fibrosis. By the time he was a teenager — well before recent medical advances for this rare genetic condition — he’d found out via internet searches he wasn’t expected to live beyond his mid-20s.
Imagine, then, how blessed this Irishman, now 27, feels to be walking the sun-kissed fairways of Royal Birkdale and about to take on the best golfers in the world at the British Open.
“Here I am, as healthy as ever and playing at the Open. It’s just nuts,” Howard said with a smile at the back of the 18th green after his first practice round, in the company of former champions Padraig Harrington and Shane Lowry. “Yeah, I’d like to think I’m an inspiration.”
Being a qualified mechanic and No. 1,456 in the world amateur rankings ensures Howard, who came through one of four local qualifying events to take his place in golf’s oldest major, is no normal British Open participant.
Also making him different is what he packs in his golf bag for each round: As important as his clubs is his medication, with Howard taking up to 30 tablets a day to prevent infection and help digest food properly.

Of the 156 players competing at this week's Open Championship, David Howard's journey to Royal Birkdale is among the most remarkable and inspiring.
For a long time, teeing it up at a major alongside the world's best golfers was nothing more than a pipe dream for the trained mechanic from county Cork.
When Howard was seven years old, he was diagnosed with cystic fibrosis, the genetic condition that causes sticky mucus to build up in the lungs and digestive system.
By his own estimate, Howard was in hospital "a few times a year" with infections.
"I remember when I first got access to a phone when I was 12, 13, I googled 'cystic fibrosis life expectancy' and it was saying mid-20s," the 27-year-old told BBC Sport NI's Stephen Watson.

Ipsen agreed to acquire Kartos Therapeutics, a Redwood City, California-based clinical-stage biopharmaceutical company developing a treatment for myelofibrosis, a rare blood cancer, for $450 million upfront and up to $1.3 billion in additional milestone payments, bringing the total potential deal value to $1.75 billion.
According to Reuters, the acquisition centers on navtemadlin, an oral MDM2 inhibitor being evaluated as an add-on therapy to ruxolitinib, the current standard of care for myelofibrosis, in patients who have a suboptimal response to that treatment. The drug is currently in a Phase III trial called POIESIS, which is enrolling more than 600 patients across more than 250 sites globally. Top-line data from that trial are expected in 2027, the company said.
Ipsen CEO David Loew said in a statement that the deal "further strengthens our late-stage oncology pipeline" and that navtemadlin has the potential to become a new treatment option as early as 2028.
Myelofibrosis is a rare blood cancer in which the bone marrow becomes scarred, forcing blood production to shift to the spleen and causing significant symptoms including fatigue, night sweats, and progressive splenomegaly. Approximately 50% to 75% of patients on ruxolitinib discontinue treatment within three years, and median overall survival after discontinuation is roughly one to two years, the company said.
The milestone payments to Kartos shareholders include a significant regulatory approval payment and sales-based milestones, Ipsen said. The deal is expected to close by the end of the third quarter, subject to antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street ****** ysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235.
The firm pointed to an upcoming data release for Insmed's experimental lung drug TPIP as a potential catalyst that investors may be underestimating. TPIP, which stands for Treprostinil Palmitil Inhalation Powder, is an inhaled therapy Insmed is developing for pulmonary arterial hypertension (PAH).
According to Cantor Fitzgerald, it has been roughly a year since Insmed first presented the Phase 2b clinical trial results for TPIP in PAH. The firm sees the next data release as a moment that could meaningfully revive investor interest in the drug. This data is a one-year open label extension update expected in Q3 2026. For context, an open label extension is the phase of a clinical study where all patients are given the actual drug and monitored over a longer period, and the data from this phase typically gives a clearer picture of how durable and safe the treatment is over time.
The firm noted that if the next data release provides robust results, the market may shift focus from Brinsupri, Insmed's drug for non-cystic fibrosis bronchiectasis. This is because the market is significantly undervaluing TPIP just because Brinsupri posted blowout revenue at the end of Q1 2026.
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company. It focuses on developing and commercializing therapies for serious and rare diseases. One of its lead approved product is ARIKAYCE, an inhaled antibiotic delivered via the Lamira Nebulizer System.

Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutics in the United States and internationally. The company has a market cap of $19.6 billion and offers JAKAFI for the treatment of myelofibrosis, ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia, and other products.
Companies with a market cap of $10 billion or more are typically referred to as "big-cap stocks." INCY fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the biotechnology industry.
Dear Microsoft Stock Fans, Mark Your Calendars for June 30
Dear Walmart Stock Fans, Mark Your Calendars for June 22
Nothing Seems to Be Going Right for Meta Platforms. How to Play META Stock Here.

Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 3 years. On June 15, Eli Lilly and Company (NYSE:LLY) shared new data from the Phase 1 AJX-101 study. The study showed that an investigational type II JAK2 inhibitor delivered an "encouraging" safety profile, demonstrating clinical activity in patients living with myelofibrosis who have failed a type I JAK2 inhibitor.
The therapy is aimed at selectively binding the type II conformation of the JAK2 kinase, thus providing improved efficacy over current solutions. It will also offer a new option for patients who develop resistance to type I JAK2 inhibitors. This addition follows the completion of the acquisition.
Copyright: kadmy / 123RF Stock Photo
Earlier on June 9, Jefferies lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330 and reiterated a Buy rating. This comes after the company reported full data from retatrutide's TRIUMPH-1 obesity study and TRANSCEND-T2D-1 study. Despite some safety concerns, which the firm believes are manageable, the retatrutide's overall profile "will be difficult to beat," the firm said. Indeed, LLY is among the stocks with the best earnings growth for the next 3 years.
Eli Lilly and Company (NYSE:LLY) is an Indiana-based company specializing in human pharmaceutical products. Founded in 1876, the company offers products for cardiometabolic health, oncology, immunology, and migraine prevention.